Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beraprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 4/20 | 0.85 |
| ▸ | PTGER3 | P43115 | 13/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | PTGFR | P43088 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beraprost SCHEMBL16121149 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16405382 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL17284532 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL18969746 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL18501474 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL6084938 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Esuberaprost SCHEMBL13174399 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL22972690 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL21778834 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL1554142 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7521 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| CN-122059915-A | Shellfish prostate method for synthesizing hormone | 南通诺泰生物医药技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12569437-B2 | Disease-site-specific liposomal formulation | OSAKA UNIVERSITY (JP) | 2026-03-10 | — | — | US | claimed |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | PHARMOSA BIOPHARM INC. (TW) | 2026-02-17 | — | — | US | claimed |
| US-20260021109-A1 | PROSTANOID RECEPTOR AGONISTS AS NON-TUBERCULOUS ANTI-MYCOBACTERIAL AGENTS | CHARIOT INNOVATIONS LTD (GB) | 2026-01-22 | — | — | US | claimed |
| US-20260014114-A1 | METHOD OF TREATING PAH WITH COMBINATIONS OF RALINEPAG AND OTHER AGENTS | CLAPP LUCIE H (GB) | 2026-01-15 | — | — | US | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007656-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, PULMONARY ARTERIAL HYPERTENSION, ADN RESPIRATORY SYNCYTIAL VIRUS | REVERSPAH LLC (US) | 2026-01-08 | — | — | US | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| EP-4356908-B1 | METHOD FOR TREATING FELINE WITH CHRONIC KIDNEY DISEASE | TORAY INDUSTRIES (JP) | 2025-10-22 | — | — | EP | claimed |
| EP-0623346-A1 | INHIBITOR FOR METASTASIS OF MALIGNANT TUMOR | TORAY INDUSTRIES, INC. (JP) | 1994-11-09 | — | — | EP | claimed |
| EP-0609336-A1 | USE OF PROSTACYCLIN DERIVATIVES TO PREVENT OR TREAT DISORDERS OF THE MICROCIRCULATING SYSTEM WHEN X-RAY, NMR OR ULTRASONIC CONTRASTING AGENTS ARE ADMINISTERED | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-08-10 | — | — | EP | claimed |
| EP-0583482-A1 | REMEDY FOR WOUND OR HEMORRHOID | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1994-02-23 | — | — | EP | claimed |
| WO-1994003175-A1 | USE OF PROSTANE DERIVATIVES OF FORMULAE I AND II FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC POLYARTHRITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-02-17 | — | — | WO | claimed |
| EP-0571462-A1 | PROSTACYCLINE AND CARBACYCLINE DERIVATIVES AS AGENTS FOR TREATING FEVERISH COMPLAINTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-12-01 | — | — | EP | claimed |
| EP-0572014-A1 | Hair-growing composition containing prostaglandin I 2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1993-12-01 | — | — | EP | claimed |
| EP-0565730-A1 | REMEDY FOR HEPATIC DISEASE | TORAY INDUSTRIES, INC. (JP) | 1993-10-20 | — | — | EP | claimed |
| WO-1993014761-A1 | PROSTACYCLIN AND CARBACYCLIN DERIVATIVES AS AGENTS IN THE TREATMENT OF MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT, BERLIN UND BERGKAMEN (DE) | 1993-08-05 | — | — | WO | claimed |
| WO-1993007875-A1 | USE OF PROSTACYCLIN DERIVATIVES TO PREVENT OR TREAT DISORDERS OF THE MICROCIRCULATING SYSTEM WHEN X-RAY, NMR OR ULTRASONIC CONTRASTING AGENTS ARE ADMINISTERED | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-04-29 | — | — | WO | claimed |
| WO-1992014438-A2 | PROSTACYCLINE AND CARBACYCLINE DERIVATIVES AS AGENTS FOR TREATING FEVERISH COMPLAINTS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-09-03 | — | — | WO | claimed |